Description: Noxopharm Limited is a drug development company. The Company is engaged in the research and development of NOX66 in the field of adjuvant therapy in chemotherapy and radiotherapy. The Company focuses on developing a drug to treat cancer. The Company has a primary focus on the development of drugs to treat the problem of drug- and radio-resistance in cancer cells. The Company's drug NOX66 is a dosage formulation developed to protect idronoxil from being inactivated in the human body by Phase II metabolism. Its purpose is to ensure that idronoxil administered remains in an active form. The Company has its offices in Melbourne and Sydney.
Home Page: www.noxopharm.com
NOX Technical Analysis
Tower A, The Zenith
Chatswood,
NSW
2067
Australia
Phone:
61 2 9144 2223
Officers
| Name | Title |
|---|---|
| Dr. Gisela Mautner | CEO, Exec. MD, Chief Medical Officer & Director |
| Mr. Shawn Van Boheemen | Chief Financial Officer |
| Ms. Jeanette Bell Ph.D. | Chief Operating Officer |
| Dr. John Wilkinson B.Sc., Ph.D. | Chief Scientific Officer of Oncology |
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Scientific Officer of Inflammation |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9387 |
| Price-to-Sales TTM: | 7.8057 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |